There is no previous study to investigate EpCAM-expressing CSCs for their tumorigenic ability in a compromised liver microenvironment such as non-alcoholic fatty liver disease (NAFLD). Here, EPCAM is linked to metabolic dysfunction-associated steatotic liver disease.